Experimental combo for resistant breast cancer shows early promise but trial halted
NCT ID NCT01589861
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a combination of two oral drugs, BKM120 and lapatinib, in 24 people with HER2-positive breast cancer that had stopped responding to trastuzumab. The goal was to find a safe dose and see if the combination could shrink tumors. The study was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BKM120 and lapatinib
- What this could lead to
- If it works, this could offer a new treatment option for patients with HER2+ breast cancer that has stopped responding to trastuzumab.
- What could go wrong
- The trial was terminated early, so results are limited. It was a small, early-phase study, and the combination may not prove effective or safe in larger groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Paoli-Calmettes
Marseille, 13008, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?